Payment overview · 2025
General Payments
$1,911.06
87 reported records · 23 companies
Healthcare provider profile · identity verified
Basil S. Hassan, MD
Allopathic & Osteopathic Physicians|Family Medicine · WEST DES MOINES, IA · NPI 1932180437
Verified facts
What the public records show
CMS Open Payments records show Basil S. Hassan, MD received $1,911.06 in general payments during 2025 across 87 reported records.
PFIZER INC. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $334.62 | 17.5% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $324.48 | 17.0% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $149.10 | 7.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $136.15 | 7.1% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $119.82 | 6.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $119.31 | 6.2% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $95.19 | 5.0% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $95.08 | 5.0% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $92.99 | 4.9% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $83.50 | 4.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.52 | 2.5% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $39.76 | 2.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.30 | 1.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.99 | 1.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.42 | 1.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.25 | 1.6% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.24 | 1.6% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.94 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.62 | 1.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.66 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.53 | 0.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.80 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.79 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,667.02 | 84 |
| Education | $244.04 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $241.24 | 18 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $225.19 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $202.81 | 12 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $149.10 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $138.65 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $136.15 | 7 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $119.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $102.59 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $95.08 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $92.99 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $73.65 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $47.52 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.15 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.15 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.15 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.30 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.99 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.42 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $31.25 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 363 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
363 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 677 | 138 |
| Gabapentin | Gabapentin | 410 | 59 |
| Eliquis | Apixaban | 363 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 63 |
| Metformin Hcl | Metformin Hcl | 272 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 268 | 42 |
| Furosemide | Furosemide | 251 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 248 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 43 |
| Lisinopril | Lisinopril | 233 | 55 |
| Omeprazole | Omeprazole | 213 | 50 |
| Simvastatin | Simvastatin | 204 | 44 |
| Sertraline Hcl | Sertraline Hcl | 200 | 45 |
| Potassium Chloride | Potassium Chloride | 165 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 145 | 28 |
| Losartan Potassium | Losartan Potassium | 128 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 29 |
| Baclofen | Baclofen | 114 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 27 |
| Carvedilol | Carvedilol | 104 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 43 |
| Trazodone Hcl | Trazodone Hcl | 101 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 15 |
| Spironolactone | Spironolactone | 97 | 18 |
| Levetiracetam | Levetiracetam | 96 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 13 |
| Bumetanide | Bumetanide | 91 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 20 |
| Memantine Hcl | Memantine Hcl | 81 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 80 | 15 |
| Xarelto | Rivaroxaban | 76 | suppressed |
| Jardiance | Empagliflozin | 74 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 17 |
| Amoxicillin | Amoxicillin | 67 | 35 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 66 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 17 |
| Donepezil Hcl | Donepezil Hcl | 63 | 15 |
| Metformin Hcl Er | Metformin Hcl | 63 | 11 |
| Cephalexin | Cephalexin | 61 | 28 |
| Trulicity | Dulaglutide | 59 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | suppressed |
| Famotidine | Famotidine | 58 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 58 | 20 |
| Tramadol Hcl | Tramadol Hcl | 57 | 15 |
| Myrbetriq | Mirabegron | 56 | suppressed |
| Prednisone | Prednisone | 56 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 53 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 11 |
| Azithromycin | Azithromycin | 52 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | suppressed |
| Hydrocortisone | Hydrocortisone | 51 | suppressed |
| Naproxen | Naproxen | 50 | 20 |
| Allopurinol | Allopurinol | 49 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | suppressed |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 18 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 14 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 18 |
| Alprazolam | Alprazolam | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | 11 |
| Humalog | Insulin Lispro | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Otezla | Apremilast | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Nyamyc | Nystatin | 23 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Dulera | Mometasone/Formoterol | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 12 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Dicloxacillin Sodium | Dicloxacillin Sodium | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Sotalol Af | Sotalol Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,911.06 · 87 records | PFIZER INC. | ABRYSVO, AUSTEDO XR, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, ELIQUIS, EVENITY, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, JOURNAVX, Kerendia, MOUNJARO, NURTEC ODT, NUZYRA, Ohtuvayre, PREVNAR 20, PROLIA, REXULTI, Symbravo, The Cologuard Plus Collection Kit, UZEDY, VOQUEZNA, VOWST, VRAYLAR, VYNDAMAX, Veozah, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error